Atom Investors LP Makes New Investment in KalVista Pharmaceuticals, Inc. $KALV

Atom Investors LP acquired a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 276,113 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,459,000. Atom Investors LP owned about 0.55% of KalVista Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. ExodusPoint Capital Management LP bought a new stake in KalVista Pharmaceuticals during the 4th quarter worth about $324,000. Spruce Street Capital LP bought a new stake in KalVista Pharmaceuticals during the 4th quarter worth about $6,266,000. Truvestments Capital LLC grew its holdings in KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after acquiring an additional 3,360 shares during the last quarter. NEXTBio Capital Management LP bought a new stake in KalVista Pharmaceuticals during the 4th quarter worth about $2,129,000. Finally, Barclays PLC grew its holdings in KalVista Pharmaceuticals by 21.2% during the 4th quarter. Barclays PLC now owns 700,573 shares of the specialty pharmaceutical company’s stock worth $11,314,000 after acquiring an additional 122,669 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have commented on KALV. Leerink Partners lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. JonesTrading lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Citizens Jmp lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Needham & Company LLC downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Finally, Stifel Nicolaus upped their target price on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Three investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $30.60.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock opened at $27.00 on Wednesday. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 1 year low of $9.83 and a 1 year high of $27.00. The company has a market cap of $1.44 billion, a PE ratio of -7.80 and a beta of -0.12. The company’s 50-day moving average is $24.44 and its two-hundred day moving average is $19.02.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The business had revenue of $40.86 million for the quarter, compared to the consensus estimate of $39.03 million. Equities analysts anticipate that KalVista Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 10,926 shares of the company’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $26.78, for a total transaction of $292,598.28. Following the transaction, the chief executive officer directly owned 479,989 shares in the company, valued at approximately $12,854,105.42. This represents a 2.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $16.95, for a total transaction of $2,960,232.75. Following the completion of the sale, the insider owned 5,129,340 shares in the company, valued at $86,942,313. This represents a 3.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 254,602 shares of company stock worth $4,656,670. Insiders own 4.30% of the company’s stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.